BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 21145801)

  • 1. Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy.
    Lange CM; Bojunga J; Ramos-Lopez E; von Wagner M; Hassler A; Vermehren J; Herrmann E; Badenhoop K; Zeuzem S; Sarrazin C
    J Hepatol; 2011 May; 54(5):887-93. PubMed ID: 21145801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vitamin D-related gene polymorphism predict treatment response to pegylated interferon-based therapy in Thai chronic hepatitis C patients.
    Thanapirom K; Suksawatamnuay S; Sukeepaisarnjaroen W; Tangkijvanich P; Treeprasertsuk S; Thaimai P; Wasitthankasem R; Poovorawan Y; Komolmit P
    BMC Gastroenterol; 2017 Apr; 17(1):54. PubMed ID: 28415985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A genetic validation study reveals a role of vitamin D metabolism in the response to interferon-alfa-based therapy of chronic hepatitis C.
    Lange CM; Bibert S; Kutalik Z; Burgisser P; Cerny A; Dufour JF; Geier A; Gerlach TJ; Heim MH; Malinverni R; Negro F; Regenass S; Badenhoop K; Bojunga J; Sarrazin C; Zeuzem S; Müller T; Berg T; Bochud PY; Moradpour D;
    PLoS One; 2012; 7(7):e40159. PubMed ID: 22808108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of CYP27B1+2838 promoter polymorphism in the treatment of chronic hepatitis B HBeAg negative with PEG-interferon.
    Boglione L; Cusato J; De Nicolò A; Cariti G; Di Perri G; D'Avolio A
    J Viral Hepat; 2015 Mar; 22(3):318-27. PubMed ID: 25060765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The vitamin D receptor gene bAt (CCA) haplotype impairs the response to pegylated-interferon/ribavirin-based therapy in chronic hepatitis C patients.
    Baur K; Mertens JC; Schmitt J; Iwata R; Stieger B; Frei P; Seifert B; Bischoff Ferrari HA; von Eckardstein A; Müllhaupt B; Geier A;
    Antivir Ther; 2012; 17(3):541-7. PubMed ID: 22300961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of vitamin D-related gene polymorphisms (CYP27B and VDR) on the response to interferon/ribavirin therapy in chronic hepatitis C.
    García-Martín E; Agúndez JA; Maestro ML; Suárez A; Vidaurreta M; Martínez C; Fernández-Pérez C; Ortega L; Ladero JM
    PLoS One; 2013; 8(9):e74764. PubMed ID: 24073221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vitamin D-related gene polymorphisms do not influence the outcome and serum vitamin D level in pegylated interferon/ribavirin therapy combined with protease inhibitor for patients with genotype 1b chronic hepatitis C.
    Arai T; Atsukawa M; Tsubota A; Kondo C; Shimada N; Abe H; Itokawa N; Nakagawa A; Okubo T; Aizawa Y; Iwakiri K
    J Med Virol; 2015 Nov; 87(11):1904-12. PubMed ID: 25964133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic polymorphisms of vitamin D pathway predict antiviral treatment outcome in slow responder naïve patients with chronic hepatitis C.
    Falleti E; Cmet S; Fabris C; Fattovich G; Cussigh A; Bitetto D; Ceriani E; Lenisa I; Dissegna D; Ieluzzi D; Rostello A; Pirisi M; Toniutto P
    PLoS One; 2013; 8(11):e80764. PubMed ID: 24244713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vitamin D status and gene transcription in immune cells.
    Morán-Auth Y; Penna-Martinez M; Shoghi F; Ramos-Lopez E; Badenhoop K
    J Steroid Biochem Mol Biol; 2013 Jul; 136():83-5. PubMed ID: 23416105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low vitamin D levels are associated with impaired virologic response to PEGIFN + RBV therapy in HIV-hepatitis C virus coinfected patients.
    Mandorfer M; Reiberger T; Payer BA; Ferlitsch A; Breitenecker F; Aichelburg MC; Obermayer-Pietsch B; Rieger A; Trauner M; Peck-Radosavljevic M;
    AIDS; 2013 Jan; 27(2):227-32. PubMed ID: 23238552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vitamin D deficiency and HCV chronic infection: what comes first?
    Bitetto D; Fabris C; Falleti E; Toniutto P
    J Hepatol; 2011 Oct; 55(4):944-5; author reply 945. PubMed ID: 21349298
    [No Abstract]   [Full Text] [Related]  

  • 12. Impact of vitamin D supplementation on sustained virological response in chronic hepatitis C genotype 4 patients treated by pegylated interferon/ribavirin.
    Esmat G; El Raziky M; Elsharkawy A; Sabry D; Hassany M; Ahmed A; Assem N; El Kassas M; Doss W
    J Interferon Cytokine Res; 2015 Jan; 35(1):49-54. PubMed ID: 25061714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vitamin A deficiency is associated with hepatitis C virus chronic infection and with unresponsiveness to interferon-based antiviral therapy.
    Bitetto D; Bortolotti N; Falleti E; Vescovo S; Fabris C; Fattovich G; Cussigh A; Cmet S; Fornasiere E; Ceriani E; Pirisi M; Toniutto P
    Hepatology; 2013 Mar; 57(3):925-33. PubMed ID: 23213086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved responses to pegylated interferon alfa-2b and ribavirin by individualizing treatment for 24-72 weeks.
    Sarrazin C; Schwendy S; Möller B; Dikopoulos N; Buggisch P; Encke J; Teuber G; Goeser T; Thimme R; Klinker H; Boecher WO; Schulte-Frohlinde E; Prinzing R; Herrmann E; Zeuzem S; Berg T
    Gastroenterology; 2011 Nov; 141(5):1656-64. PubMed ID: 21784046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vitamin D levels in Egyptian HCV patients (genotype 4) treated with pegylated interferon.
    Mohamed AA; Sabry NA; Abbassi MM; Ibrahim WA; Ali-Eldin ZA
    Acta Gastroenterol Belg; 2013 Mar; 76(1):38-44. PubMed ID: 23650781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vitamin B12 supplementation improves rates of sustained viral response in patients chronically infected with hepatitis C virus.
    Rocco A; Compare D; Coccoli P; Esposito C; Di Spirito A; Barbato A; Strazzullo P; Nardone G
    Gut; 2013 May; 62(5):766-73. PubMed ID: 22810757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-10 promoter gene polymorphisms and sustained response to combination therapy in Taiwanese chronic hepatitis C patients.
    Chuang JY; Yang SS; Lu YT; Hsieh YY; Chen CY; Chang SC; Chang CS; Yeh HZ; Kao JH
    Dig Liver Dis; 2009 Jun; 41(6):424-30. PubMed ID: 19004675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vitamin D supplementation improves response to antiviral treatment for recurrent hepatitis C.
    Bitetto D; Fabris C; Fornasiere E; Pipan C; Fumolo E; Cussigh A; Bignulin S; Cmet S; Fontanini E; Falleti E; Martinella R; Pirisi M; Toniutto P
    Transpl Int; 2011 Jan; 24(1):43-50. PubMed ID: 20649944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of virus genotype on interferon treatment of patients with chronic hepatitis C: a multicenter controlled study.
    Xie Y; Xu DZ; Lu ZM; Luo KX; Jia JD; Wang YM; Zhao GZ; Zhang SL; Zhang DZ
    Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):369-74. PubMed ID: 15313671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vitamin D pathway gene polymorphisms and hepatocellular carcinoma in chronic hepatitis C-affected patients treated with new drugs.
    Cusato J; Boglione L; De Nicolò A; Favata F; Ariaudo A; Mornese Pinna S; Guido F; Avataneo V; Cantù M; Carcieri C; Cariti G; Di Perri G; D'Avolio A
    Cancer Chemother Pharmacol; 2018 Mar; 81(3):615-620. PubMed ID: 29356898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.